- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Anne L. Schwartz Explains Data on Newly-Eligible Medicaid Enrollees
Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission, explains the core messages of new data on average spending for new Medicaid enrollees.
Anne L. Schwartz, PhD, executive director of the Medicaid and CHIP Payment and Access Commission, explains the core messages of new data on average spending for new Medicaid enrollees.
Transcript
In December, MACSTATS included, for the first time, state-by-state enrollment and benefit spending for adults who became eligible for Medicaid under the Patient Protection and the Affordable Care Act (ACA). Can you explain the key takeaways?
We don’t have a pre-ACA information on this population because they were not covered under the Medicaid program. So, we are pleased to have for the first time data at the state level of what the average spending for these enrollees is. There are really 2 core messages. One is there is a lot of variation across state in what per enrollee spending is for the new adult group and some of that reflects differences in prices across geographic areas. It’s very expensive to provide care in Alaska less so than in other states. That’s similar to what you see in other aspects of the program.
The other thing that you see is that spending per enrollee for the new adult group is in practically every state much lower than spending on average for all the other Medicaid enrollees and that is perhaps not a surprising finding because much of the Medicaid population is sick, chronic conditions, significant disabilities, and therefore use a considerable amount of medical long-term services and supports.
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More
